Saturday 17 October 2026
Export GMAB’s income statement to Excel — free account
Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
37.00
0.82
−2.17%
Follow GMAB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 6 | 6 | 6 | 3 | 6 | — | — | — | — |
P/E ratio |
19.87 | 11.79 | 33.10 | 36.47 | 53.46 | 36.96 | 33.54 | 7.73 | 2.99 | 6.11 |
P/S ratio |
5.15 | 4.29 | 8.77 | 13.61 | 19.17 | 17.11 | 17.48 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.78 | 8.61 | 26.12 | 44.31 | 42.48 | 54.26 | 53.50 | 87.45 | — | 104.68 |
P/FCF ratio |
0.00 | 12.54 | 21.79 | 62.08 | 87.54 | 28.48 | 39.11 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.21 | 10.19 | 17.49 | 18.93 | 17.38 | 18.47 | 20.73 | 25.28 | — | 18.69 |
Beneish M-Score |
(3.00) | 1.61 | (2.96) | (1.89) | (2.38) | (2.33) | (1.64) | — | — | — |
P/Operating CF |
63.60 | 34.44 | 88.04 | 358.44 | 657.67 | (177.00) | 515.87 | 6.36 | 6.36 | 6.36 |
P/B ratio |
3.27 | 2.61 | 4.57 | 7.24 | 7.33 | 9.05 | 6.68 | 0.81 | 0.81 | 0.81 |
Price to Tangible BV |
0.00 | 4.39 | 4.58 | 7.28 | 7.41 | 9.21 | 6.91 | 0.86 | 0.86 | 0.86 |
EV/Sales |
6.10 | 3.38 | 7.11 | 12.13 | 16.94 | 15.55 | 15.47 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
19.98 | 10.23 | 22.00 | 27.84 | 47.61 | 24.91 | 20.54 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
19.14 | 9.37 | 15.86 | 45.24 | 64.49 | 24.44 | 34.61 | 0.00 | 0.00 | 0.00 |
EV/FCF |
(3.73) | 9.88 | 17.66 | 55.29 | 77.35 | 25.89 | 34.61 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
2.01 | 5.23 | 13.32 | 15.57 | 14.50 | 15.00 | 14.88 | 16.77 | 18.53 | 11.89 |
Current Ratio |
2.02 | 5.24 | 13.34 | 15.57 | 14.50 | 15.00 | 14.88 | 16.77 | 18.53 | 11.89 |
Net Debt/EBITDA |
3.13 | (2.86) | (5.01) | (3.23) | (5.80) | (2.39) | (3.89) | (4.16) | (3.84) | (3.58) |
Debt/Assets |
40.97% | 0.00% | 0.00% | 2.00% | 1.65% | 1.63% | 1.20% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.90 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.39 | 0.54 | 0.51 | 0.50 | 0.38 | 0.56 | 0.45 | 0.46 | 1.03 | 0.29 |
Operating CF/Net income |
1.23 | 0.99 | 1.70 | 0.71 | 0.74 | 1.35 | 0.61 | 0.69 | 1.44 | 0.28 |
Capex/Depreciation |
(102.39) | (1.19) | (1.27) | (0.88) | (1.02) | (1.19) | (0.80) | (5.45) | 0.00 | 0.00 |
Interest Coverage |
3.96 | 3.34 | 5.65 | 9.35 | 4.30 | 4.05 | 376.86 | 122.29 | 62.09 | 63.82 |
| 17.53% | 23.30% | 14.91% | 21.08% | 14.81% | 28.95% | 19.24% | 20.46% | 20.98% | 19.87% | |
| 9.99% | 19.64% | 13.43% | 19.06% | 13.37% | 26.46% | 17.99% | 22.39% | 47.86% | 18.64% | |
ROIC |
7.08% | 27.83% | 95.70% | 69.44% | 57.78% | 116.54% | 50.60% | 45.21% | 0.00% | 0.00% |
Return on Tangible Assets |
59.78% | 34.41% | 13.77% | 20.19% | 13.81% | 26.45% | 16.33% | 20.59% | 18.89% | 26.27% |
Average Days of Receivables |
113.03 | 109.58 | 109.61 | 151.38 | 146.22 | 97.90 | 203.38 | 160.10 | 98.31 | 196.17 |
Research and Development Expense of Revenue |
43.17% | 45.31% | 46.32% | 38.11% | 49.29% | 31.03% | 44.47% | 47.31% | 34.04% | 34.14% |
Selling, General and Administrative Expense of Revenue |
16.83% | 17.59% | 20.01% | 18.34% | 15.13% | 6.54% | 6.37% | 7.06% | 6.22% | 5.62% |
Intangible Assets out of Total Assets |
0.74 | 0.32 | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 | 0.06 | 0.00 | 0.03 |
Share Based Compensation of Revenue |
3.44% | 3.36% | 3.56% | 3.01% | 3.65% | 1.98% | 2.74% | 3.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.22) | 0.20 | 0.20 | 0.13 | 0.12 | 0.10 | 0.14 | 1.08 | 1.08 | 1.08 |
Graham Number |
18.11 | 17.85 | 12.38 | 12.56 | 9.48 | 10.55 | 7.08 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
5.03% | 8.48% | 3.02% | 2.74% | 1.87% | 2.71% | 2.98% | 12.93% | 33.43% | 16.36% |
Free Cash Flow Yield |
(31.78%) | 7.97% | 4.59% | 1.61% | 1.14% | 3.51% | 2.56% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
5.99 | 4.86 | 3.66 | 3.16 | 2.06 | 2.38 | 1.28 | 0.78 | 0.62 | 0.43 |
Operating CF per Share |
1.91 | 1.75 | 1.64 | 0.85 | 0.54 | 1.51 | 0.32 | 0.26 | 0.41 | 0.08 |
Capex per Share |
(11.70) | (0.11) | (0.08) | (0.07) | (0.06) | (0.07) | (0.03) | (0.12) | 0.00 | 0.00 |
Free Cash Flow per Share |
(9.79) | 1.64 | 1.56 | 0.78 | 0.48 | 1.44 | 0.29 | 0.14 | 0.41 | 0.08 |
Cash per Share |
2.76 | 4.60 | 6.26 | 4.83 | 4.70 | 3.78 | 2.61 | 1.58 | 1.41 | 0.92 |
Shareholders Equity per Share |
9.41 | 8.00 | 7.03 | 5.94 | 5.40 | 4.49 | 3.34 | 2.07 | 1.63 | 1.13 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.41 | 8.00 | 7.03 | 5.94 | 5.40 | 4.49 | 3.34 | 2.07 | 1.63 | 1.13 |
Free Cash Flow |
(6,084.00) | 1,054.89 | 1,016.98 | 509.05 | 314.38 | 938.50 | 182.13 | 85.13 | 255.88 | 46.52 |
Working Capital |
1,458.00 | 3,156.00 | 4,451.11 | 3,760.05 | 3,367.83 | 2,686.82 | 1,952.15 | 1,107.16 | 923.03 | 636.31 |
Capital Expenditures |
(7,270.00) | (71.11) | (54.60) | (44.89) | (40.09) | (47.03) | (16.64) | (75.61) | (14.33) | (4.68) |
Net Current Asset Value |
(4,141.00) | 2,623.00 | 4,277.59 | 3,616.46 | 3,230.53 | 2,569.01 | 1,928.46 | 1,106.64 | 922.38 | 636.31 |
EV/EBIT |
21.32 | 10.86 | 22.00 | 27.84 | 47.61 | 24.91 | 31.46 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.95 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.16 | 0.00 | 0.00 |
Price to Operating Income |
17.97 | 13.78 | 27.14 | 31.26 | 53.88 | 27.40 | 23.21 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.46 | 0.44 | 0.31 | 0.45 | 0.40 | 0.57 | 0.59 | 0.54 | 0.62 | 1.28 |
Cash ROIC |
(47.40%) | 13.04% | 11.72% | 7.14% | 4.71% | 17.24% | 4.82% | 3.81% | 13.59% | 3.75% |
Accounts Receivable Turnover |
3.56 | 3.77 | 3.04 | 2.96 | 2.82 | 3.59 | 2.44 | 3.06 | 3.16 | 2.14 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
17.63 | 16.55 | 0.00 | — | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
27.61 | 22.97 | 92.06 | — | — | — | — | — | — | — |
Average Receivables |
1,044.50 | 827.65 | 787.70 | 698.86 | 478.05 | 431.84 | 329.19 | 156.38 | 120.51 | 120.51 |
Average Payables |
— | — | — | 44.21 | 124.41 | 160.85 | 87.32 | 27.53 | 4.86 | 4.86 |
Average Inventory |
13.50 | 8.64 | — | — | — | — | — | — | — | — |
Average Assets |
9,643.50 | 5,768.98 | 4,705.66 | 4,102.76 | 3,578.63 | 2,754.60 | 1,805.15 | 1,041.60 | 371.49 | 903.13 |
Average Common Equity |
5,492.00 | 4,863.39 | 4,237.71 | 3,708.51 | 3,230.36 | 2,517.57 | 1,687.64 | 1,139.73 | 847.33 | 847.33 |
Columns are period end dates